Key clinical point: Adjuvant chemotherapy improves outcomes in patients with locally advanced upper tract urothelial cancer.
Major finding: Compared with surveillance, platinum-based chemotherapy started within 90 days after nephroureterectomy sharply reduced the risk of disease-free survival events (hazard ratio, 0.45; P = .0001).
Study details: A phase 3, randomized trial of 261 patients with locally advanced upper tract urothelial cancer.
Disclosures: The trial was funded by Cancer Research UK. The authors disclosed relationships with numerous pharmaceutical companies.
Birtle A et al. Lancet. 2020 Mar 5. doi: 10.1016/S0140-6736(20)30415-3.